drugset / Trial / NCT02182388

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

NCT02182388

Phase 1 Completed 82 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this trial was to investigate the safety, tolerability, pharmacokinetics, and relative bioavailability of BI 207127 NA as powder in the bottle (PIB) and solid oral dosage form (tablets) without and with food.

Timeline

Start
2007-01
Primary completion
2007-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Deleobuvir Small molecule Oral

Indications

No indication recorded.